Acceptability of Hybrid Closed-loop Systems in Patients Living With Highly

Status Completed

Clinical Trial Summary

While closed-loop insulin delivery (CLID) systems demonstrated safety and effectiveness in patients with unbalanced type 1 diabetes (T1D), no studies have included patients with highly and chronically unbalanced diabetes. The investigators conduct a retrospective, observational, and single-center study to evaluate the acceptability, safety, and efficacy of a CLID system in patients living with T1D (≥2 years) with a HbA1c>11% in the past 12 months and a mean HbA1c >10% over the past three years. Efficacy was assessed using continuous glucose monitoring parameters.

Clinical Trial Description

If hybrid closed-loop systems (HCLS) ("artificial pancreas") for automated insulin administration have demonstrated their great interest in patients living with moderately unbalanced type 1 diabetes (T1D) (HbA1c < 8 .6% on average), no study has looked at their safety, acceptability and efficacy in patients living with highly and chronically unbalanced T1D (HbA1c > 11%). These patients, often young, present more or less advanced microangiopathic complications (retinopathy, nephropathy, neuropathy, etc.) or are highly exposed to the appearance of these complications, the prevention of which, whether primary or secondary, involves obtaining a good glycemic balance over time. These patients "escape" the possibilities of current insulin therapy, whether by multiple insulin injections or by insulin pump, more or less coupled to a continuous glucose monitoring system. Automated insulin delivery systems could be a solution to achieve less catastrophic glycemic control in some of these patients. The investigators are proposing a pilot study aimed at evaluating acceptability, safety and effectiveness of a HCLS currently available in France (the SMARTGUARD™ MINIMED™ 780G or the Control-IQ) in patients followed in the diabetology department of the Centre Hospitalier Sud-Francilien (CHSF), living with highly unbalanced T1D (HbA1c > 11%) in the context of usual follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05282264
Study type	Observational
Source	Centre Hospitalier Sud Francilien
Contact
Status	Completed
Phase
Start date	April 1, 2022
Completion date	December 11, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05653518` - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes	N/A
Enrolling by invitation	`NCT05515939` - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed	`NCT05109520` - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting	`NCT04016987` - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes	N/A
Active, not recruiting	`NCT04190368` - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes	N/A
Recruiting	`NCT05413005` - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus	Early Phase 1
Active, not recruiting	`NCT04668612` - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes	N/A
Completed	`NCT02837094` - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1	Phase 1
Recruiting	`NCT05414409` - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action	Phase 2
Recruiting	`NCT05670366` - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes	N/A
Active, not recruiting	`NCT05418699` - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed	`NCT04084171` - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6	N/A
Recruiting	`NCT06144554` - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting	`NCT05153070` - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes	Phase 2
Recruiting	`NCT05379686` - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes	N/A
Completed	`NCT05281614` - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D	Early Phase 1
Withdrawn	`NCT04259775` - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes	N/A
Active, not recruiting	`NCT01600924` - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed	`NCT02750527` - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed	`NCT02914886` - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Acceptability of Hybrid Closed-loop Systems in Patients Living With Highly Unbalanced Type 1 Diabetes — HCL-VHP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms